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Phenylalanine metabolism in uremic and normal man. The
metabolism of phenylalanine and tyrosine was evaluated in six
normal men, five chronically uremic men, and three men undergo-
ing maintenance hemodialysis. Phenylalanine, tyrosine, and 13
acidic metabolites of those amino acids were measured in plasma
postabsorptively and in plasma and urine after a phenylalanine
load of 100 mg/kg. In addition, five normal subjects and five
dialysis patients ingested L-['4C]-phenylalanine (uniformly la-
beled) with the load. In uremic and dialysis patients, plasma
phenylalanine rose higher and fell more gradually after the load,
and tyrosine rose more slowly. The 24-hr urinary concentrations of
phenylalanine and tyrosine were similar in the three groups. At 24
hr, cumulative expiration of "CO2 was 20.2% in the dialysis
patients and 28.4% in the normal subjects. Plasma phenylalanine
levels and "CO2 expiration varied with protein intake in normal
subjects. In uremic and dialysis patients, plasma phenyllactic acid,
p-hydroxyphenylacetic acid, and p-hydroxybenzoic acid were ele-
vated, the last one markedly so. Moreover, plasma phenylpyruvic
acid (PPA) and mandeic acid were detected only in dialysis
patients. After the phenylalanine load, plasma conjugated phenyla-
cetic acid rose in uremic patients, and PPA increased transiently in
some dialysis patients. In urine of dialysis patients, concentrations
of benzoic acid and conjugated o-hydroxyphenylacetic acid were
decreased, and PPA was sometimes increased. The data suggest a
mild impairment in the hydroxylation of phenylalanine which does
not result in marked changes in plasma or in urinary metabolites
after a phenylalanine load.
Métaholisme de Ia phénylalanine chez l'homme normal et
I'homme urémique. Le métabolisme de Ia phénylalanine et de Ia
tyrosine a éte étudié chez six sujets normaux, cinq malades at-
teints d'insuffisance rénale chronique et trois hommes soumis a
l'hemodialyse iterative. La phénylalanine, Ia tyrosine et 13 métab-
olites acides de ces acides aminés ont été doses dans le plasma
après absorption et dans Ic plasma et l'urine après une charge de
phenylalanine (100 mg/kg). De plus cinq sujets normaux et cinq
malades en hémodialyse ont ingéré de la L-["C]-phénylalanine (ul)
en méme temps que Ia charge. Chez les malades urémiques et en
dialyse Ia concentration plasmatique de Ia phenylalanine augmente
plus et diminue plus lentement après Ia charge alors que Ia tyrosine
augmente plus lentement. L'excrétion urinaire de 24 hr de phCnyl-
alanine et de tyrosine est semblable dans les trois groupes. A 24 hr
le "CO2 expizé cumulé est de 20,2% chez les malades en dialyse et
de 28.4% chez les sujets normaux. Les concentrations plasma-
tiques des acides phényllactique, p-hydroxyphénylacetique et p-
hydroxybenzoique sont élevées, surtout pour ce demier. De plus,
les acides phénylpyruvique et mandélique ne sont détectés que
dans le plasma des sujets en dialyse. Après Ia charge, l'acide
phénylacetique conjugué du plasma augmente chex les malades
urémiques et l'acide phénylpyruvique augmente transitoirement
chez quelques malades en dialyse. Dans l'unne des malades en
dialyse les acides benzoiques et o-hydroxyphénylacétique co-
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njugué sont diminués et l'acide phénylpyruvique parfois aug-
menté. Ces résultats suggèrent une alteration modérée de
l'hydroxylation de la phénylalanine qui n'entraine pas de modifica-
tions importantes des métabolites plasmatiques ou urinaires après
une charge en phenylalanine.
The ratio of tyrosine to phenylalanine in plasma
has been shown by many investigators to be reduced
in renal failure. Moreover, in renal failure, plasma
phenylalanine and tyrosine respond abnormally to a
phenylalanine load, suggesting that the conversion of
phenylalanine to tyrosine is impaired [1, 2]. The
metabolism of tyrosine in chronic renal failure ap-
pears to be normal, as indicated by in vivo kinetic
studies using tyrosine labeled with radioactive car-
bon ('4C) [3]. The clinical significance of these find-
ings is unclear, and some investigators have ques-
tioned whether the accumulation of phenylalanine
metabolites other than tyrosine may contribute to
uremic toxicity [4, 5].
The present study was undertaken to investigate
further phenylalanine metabolism in normal sub-
jects, patients with chronic uremia, and patients
undergoing maintenance hemodialysis. Phenylala-
nine, tyrosine, and certain of their metabolites were
measured in plasma and urine in the postabsorptive
state and after ingestion of a phenylalanine load. In
some normal subjects and hemodialysis patients, a
tracer dose of L-phenylalanine uniformly labeled
with carbon-14 was administered with the phenylala-
nine load. Expiration of '4C02, urinary excretion of
carbon-14, and the quantity of carbon-14 in plasma
proteins were measured.
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Methods
Subjects. Eleven normal men, five men with
chronic uremia, and eight men undergoing mainte-
nance hemodialysis were studied. Their characteris-
tics are given in Table I. The patients with chronic
uremia and the patients undergoing dialysis were
clinically stable, and none had diabetes mellitus,
liver disease, or inflammatory or catabolic diseases
other than uremia.
Four normal subjects lived in a metabolic research
unit and ingested rigidly controlled diets that pro-
vided 40 g/day of protein of primarily high biological
value for 21 (sD)7 days (range, 11 to 27 days) prior
to the study. Seven normal subjects ingested their
usual diets ad jib. One normal subject was studied
both after eating 40 g of protein and his usual 90-g
protein diet. The uremic and dialysis subjects were
outpatients. One chronically uremic patient was re-
studied after he had received dialysis therapy for
4 months. Mean calculated dietary protein intake of
these seven normal subjects and the chronically
uremic and dialysis patients were 98 21, 56 11,
and 91 17 g/day, respectively.
Load tests. Subjects fasted from midnight until
approximately 8:30 A.M. and then drank a suspen-
sion of L-phenylalanine (Ajinomoto, Inc.), 100 mg/kg
of body wt, in 400 ml of water. The container was
then rinsed with 300 ml of water which the subjects
drank. Blood was collected 5 mm before administer-
ing the phenylalanine and 30, 60, 90, 120, 180, and
240 mm afterwards. In some subjects, blood samples
were also obtained 24 hr following the load, after a 9-
hr fast. Subjects voided 5 or 10 mm before drinking
the phenylalanine suspension, and urine was then
collected for the next 24 hr. After ingesting the load,
subjects were fasted until blood sampling was com-
pleted at 240 mm. They then were encouraged to eat
their usual total daily food intake, including break-
fast. Dialysis patients received the load test either 15
hr (three patients) or 61 hr (five patients) after the
termination of a dialysis treatment.
Five normal and five hemodialysis subjects re-
ceived tracer L-['4C]-phenylalaflifle (uniformly la-
beled), 0.3 p.Ci/kg of body wt, with the phenylalanine
suspension. Immediately afterwards, each subject
sat in an easy chair and wore a plastic helmet that
formed an almost air-tight seal. Air was pumped into
the helmet and was evacuated at a slightly greater
rate (10 liters/mm) to create a small degree of nega-
tive pressure within the helmet. The evacuated air,
which included carbon dioxide expired from the sub-
ject, flowed through an ion chamber (Cary Instru-
ments) and a carbon dioxide analyzer (Godart Cap-
nograph®). Ion currents generated by carbon-14 in
the ion chamber were detected by a vibrating reed
electrometer (Cary Instruments). Expiration of total
carbon dioxide and '4C02 was monitored continu-
ously for the first 4 hr and periodically for the next 20
hr. Data from the present and previous studies indi-
cate that the times of measurement of total carbon
dioxide and '4C02 were sufficient to determine the 24
hr expiration of these gases.
General analytical procedures. Plasma samples
were deproteinized for amino acid analysis by mixing
them with sulfosalicylic acid (SSA), 45 mg per ml of
plasma, and centrifuging them at 3,000 rpm for 10
mm. Urine samples were not deproteinized, but the
pH was adjusted to 2.2. Phenylalanine and tyrosine
were analyzed with an amino acid analyzer (Beck-
man 120 HP or 121 M). Urea and creatinine were
measured with an autoanalyzer (Technicon).
Total radioactivity in urine, in deproteinized
plasma, and in plasma proteins was measured with a
liquid scintillation counter (Beckman LS 3150T) us-
ing Biofluor® (New England Nuclear) scintillation
liquid. For measurement of radioactivity in plasma
proteins, the SSA precipitate was dissolved in a two
percent aqueous solution of unlabeled phenylalanine
to wash out any labeled phenylalanine noncovalently
bound to protein. The proteins were reprecipitated
with concentrated hydrochloric acid, reconstituted in
0.5 N sodium hydroxide, and added to the Biofluor®
scintillation liquid. Because of chemiluminescence,
several days of dark adaptation were necessary be-
fore the counts stabilized. To calculate the quantity
Table 1. Clinical characteristics of subjectsa
No. of
subjects
Age
yr
Wt
kg
Serum urea
nitrogen
,ng/dl
Serum
creatinine
mg/cl!
Urea
clearance
mi/mm
Creatinine
clearance
mI/,nin
Normal 11 43 10 76 10 15 7 1.0 0.4 48 14 135 40
Chronically uremic 5 49 10 83 II 55 7 8.9 2,0 6 2 IS 6
Hemodialysis 8 53 5 82 15 60 28 14.7 4.6 1(0..5)b 2(..6)b
a Except where indicated by footnote, values represent the mean SD.
b Mean (range); distribution not Gaussian.
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of radioactivity in total plasma protein, the radioac-
tivity was first determined in the protein present in
each milliliter of plasma. Total plasma volume was
estimated by multiplying body weight by 0.045.
For measurement of 14C02 expiration, the area
under the activity-time curve was measured by a disc
integrator. The rate of total carbon dioxide expira-
tion was similar in all subjects and did not vary
greatly during the study.
Gas chromatographic analyses of metabolites in
plasma and urine. Ten-milliliter aliquots of either
plasma or urine were acidified, saturated with so-
dium chloride, and extracted with ethyl acetate.
Plasma extracts were then shaken with 2 N aqueous
sodium hydroxide. The aqueous portion was sepa-
rated, acidffied, saturated with sodium chloride, and
extracted with ethyl acetate. The ethyl acetate ex-
tracts of plasma or urine were dried under a stream
of air. Deproteinized plasma, 0.5 ml, was mixed with
0.5 ml of concentrated hydrochloric acid and heated
in a sealed glass tube for 12 hr at 90° C. Five-milliliter
aliquots of urine were mixed with 5 ml of concen-
trated hydrochloric acid and heated for 12 hr at 90°
C. Extraction of hydrolyzed plasma or urine was
carried out as with unhydrolyzed specimens. For
derivatization, dried residues of the extracts of
plasma or urine were dissolved in 50 l of N,O-Bis-
(trimethylsilyl)-trifluoracetamide (BSTFA, Pierce
Chem. Co.), allowed to stand for 15 mm at room
temperature, and then injected into the gas
chromatograph.
Analyses were carried out with a gas chromato-
graph (Hewlett-Packard Model 700) for phenylacetic
acid (PAA), benzoic acid (BA), phenyllactic acid
(PLA), phenylpyruvic acid (PPA), mandelic acid
(MA), o-hydroxyphenylacetic acid (OHPAA), m-
hydroxyphenylacetic acid (MHPAA), hippuric acid,
p-hydroxyphenylacetic acid (PHPAA), p-hydroxy-
benzoic acid (PHBA), p-hydroxyphenylpyruvic acid
(PHPPA), p-hydroxyphenyllactic acid (PHPLA),
and homogentisic acid. The chromatographic condi-
tions were similar to those used by Wadman et al [6].
The volumes injected were s i of plasma extract
and 1 pi of urine extract. Linear calibration curves
were obtained for each compound assayed. All stan-
dards gave a single peak.
O-chlorobenzoic acid (OCBA) was used as an
internal standard, added prior to extraction. Recov-
eries from plasma for the compounds assayed were
greater than 90% except for PPA. This latter com-
pound was partially decomposed by extraction in 2 N
sodium hydroxide, resulting in an average recovery
of 52%. Upon repeated injections of the same sam-
ple, the coefficient of variation for most of the com-
pounds was 5% or less. For PAA, however, the
coefficient of variation was 20%.
Chromatographic peak assignments in three
plasma specimens were independently analyzed by
gas chromatography/mass spectrometry (GC/MS).
With the exception of PHPPA, all peak assignments
were confirmed. A large peak having the same reten-
tion time as PHPPA was found to contain no
PHPPA. The peak initially identified as PHPAA was
found to be a mixture of PHPAA and PHBA.
PHPAA and PHBA were found to have approxi-
mately equal detector responses on our instrument.
Therefore, all data derived from this peak are re-
ported as the sum of the concentrations of PHPAA
and PHBA and are referred to as PHPAA + PHBA.
These compounds were separated on the column
used in the GC/MS system (vide info).
Informed consent was obtained from all subjects.
Statistical analyses were performed with Student's t
test, paired t test, linear regression analysis, and
Wilcoxon Rank Sum test.
Results
Plasma phenylalanine. Fasting phenylalanine con-
centrations and the rates of rise in concentration
during the first 30 mm afte: the load were similar in
the three groups (Fig. I). The plasma concentration
of phenylalanine then rose higher in the uremic and
dialysis patients and in each group was significantly
greater than it was in normal subjects at 120 and 240
mm. Phenylalanine concentrations in the uremic and
dialysis patients did not differ from each other. The
time from ingestion of the phenylalanine load until
attainment of the highest plasma values was 55 23
mm in the normal subjects and tended to be longer in
the uremic patients (84 33 mm, 0.05 < P < 0.1)
and dialysis patients (94 34 mm, P <0.01). After
the maximum plasma concentration was reached, the
mean half-life (mm) of plasma phenylalanine was 140
21 in the normal subjects, and significantly greater
in the uremic patients (194 62, P <0.02) and the
dialysis patients (203 52, P < 0.005). Plasma
phenylalanine concentrations after the load tended to
be higher in the normal subjects ingesting 40 g of
protein/day as compared to those eating 80 to 120 g
of protein/day (Fig. 2).
Plasma tyrosine. Fasting plasma tyrosine concen-
trations were significantly lower in the uremic (P <
0.02) and dialysis patients (P <0.0001) as compared
with normal subjects (Fig. 3). The fasting plasma
tyrosine concentrations in the uremic and dialysis
patients taken together correlated directly with the
glomerular filtration rate (GFR) (r = 0.595, P <
0.05).
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Fig. 1. Mean plasma phenylalanine concentrations in normal
subjects (open circles, N = 11), chronically uremic patients
(closed circles, N = 5), and hemodialysis patients (x's, N = 8)
during ftsting and after a phenylalanine load. Vertical lines indi-
cate standard deviations. Superscripts a,b,c,d denote values that
were significantly different from those of normal subjects: P <
0.05, P < 0.01, P < 0.005 and P < 0.0001, respectively.
After ingestion of the phenylalanine load, plasma
tyrosine concentrations rose approximately twice as
rapidly in the normal subjects as they did in the
uremic patients and three times as fast as they did in
the dialysis patients (Fig. 3). Tyrosine concentrations
were significantly different at most times between
any two groups. Plasma tyrosine concentrations in
the normal subjects ingesting unregulated diets and
40-g protein diets were similar.
Plasma tyrosine concentrations 24 hr after the phe-
nylalanine load were 43 and 38 tmoles/liter in two
normal subjects and 34 8 in four dialysis patients.
These values did not differ from each other or from
values prior to ingestion of the load in the same
subjects. The plasma tyrosine/phenylalanine ratios at
each sampling before and after the load were signifi-
cantly lower in the uremic and dialysis patients than
they were in normal subjects. During fasting, the
ratios in the combined group of uremic and dialysis
patients correlated directly with the GFR (r =0.565,
P <0.05).
Radioactivity in plasma. The percent of ingested
carbon-14 present in the total plasma pool of SSA-
precipitable proteins was 2.3 1.2 in the normal
subjects and 1.9 1.5 in the dialysis patients at 4 hr
and 5.4 3 and 5.6 1.4, respectively, at 24 hr. The
I
Fig. 2. Mean plasma phenylalanine concentrath)ns during flisting
and dter a phenylalanine load in normal subjects ingesting 80 to
120 g of protein/day (open circles, N = 7 or 40 g of protein/day(triangles. N = 4). Vertical lines indicate standard deviations.
Asterisk indicates that the value was significantly different from
that of subjects ingesting 80 to 120 g of protein: P < 0.05.
I
Time, rn/n
Time, rn/n
250
Time, rn/n
Fig. 3. Mean plasma tyrosine concentrations in normal subjects
(open circles, N = 11), chronically uremic patients (closed circles,
N = 5), and hemodialysis patients (x's, N = 8) during fasting and
after a phenylalanine load. Vertical lines indicate standard devia-
tions. Superscripts a,b,c,d,e denote values that were significantly
different from normal subjects: P < 0.05, P < 0.02, P <0.01, P <
0.005, and P < 0.0001, respectively. Superscriptsf and g denote
values that were significantly different from chronically uremic
patients: P < 0.02 and P < 0.01, respectively.
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radioactivity in the protein-poor plasma filtrate at 24
hr was 0.2 0.1% and 2.2 1.8% of the ingested
dose in the normal and dialysis subjects (P <0.01).
Thus, the portion of the ingested label retained in
plasma at 24 hr was approximately 6% in the normal
subjects and 8% in the dialysis patients.
Expiration of '4C02. During the first four hours
after the load, the cumulative expiration of 14C02
rose more than twice as rapidly in normal subjects as
it did in dialysis patients (Fig. 4). After the first four
hours, the rate of 14C02 expiration was only slightly
greater in the normal subjects. The total '4C02 ex-
pired during the 24-hr period was 28.4 3.5% of the
ingested label in the normal subjects and 20.2 2.8%
in the dialysis patients (P < 0.005). Ingestion of
meals was not associated with significant changes in
14C02 expiration (Fig. 4).
Cumulative expiration of '4C02 in three normal
subjects receiving 40 glday of protein, as compared
with two normal subjects ingesting unregulated diets,
was usually significantly less during each of the first
10 hr after the load. Subsequently, cumulative expi-
ration, although lower in the former subjects, did not
differ significantly from the normal individuals eating
unregulated diets. The cumulative expiration of
14C02 in normal subjects ingesting the 40-g protein
diet was significantly greater at each measurement
than it was in the dialysis patients.
In the dialysis patients, the total amount of 14C02
expired during the 24 hr was directly correlated with
the GFR (r = 0.77, P < 0.05). The cumulative 14C02
expiration at 24 hr was significantly greater, 21.8
2.5%, in the three patients studied approximately 15
hr after dialysis as compared to that of 17.9 0.3%
in the two patients evaluated 61 hr after dialysis (P <
0.05).
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Urinary excretion of phenylalanine, tyrosine, and
carbon-14. The urinary excretion of phenylalanine
and tyrosine during the 24-hr period after the load did
not differ significantly among the three groups, al-
though the mean level for each amino acid was low-
est in the dialysis patients (Table 2). Also, the tyro-
sine/phenylalanine ratios in urine were similar for the
three groups.
Urinary excretion of the carbon-14 label during
this 24-hr period was 2.6 0.6% of the ingested dose
in the normal subjects and lower, 0.23% (range,
0.001 to 0.87), in the dialysis patients (P <0.01). In
the dialysis patients, urinary excretion of the carbon-
14 label was directly correlated with the GFR (r =
0.995, P <0.001).
Metabolic products oJ'phenylalanine in plasma. In
each group of subjects, plasma concentrations of free
and conjugated PAA during fasting and after the
phenylalanine load were greater than those of all
other phenylalanine metabolites combined (Table 3).
Free PAA was observed in every sample, and conju-
gated PAA was identified in most plasma specimens
from each of the three groups. Plasma free PAA
concentrations were similar in the three groups at all
times, and after the load they did not change in any
group. Mean levels of conjugated PAA tended to rise
more alter the load, particularly in the uremic pa-
tients (Table 3), and the increment in plasma conju-
gated PAA at 240 mm was greater in the uremic
patients as compared to that in normal subjects (P =
0.05). Plasma conjugated PAA was significantly
greater in the dialysis patients than it was in normal
subjects at 120 and 240 mm.
Free BA, PAA, PLA, and MA were found only
occasionally in the subjects both before and after the
load. When identified, these metabolites tended to be
higher in the dialysis and uremic patients. There was
no significant change in their concentrations after the
load. Free OHPAA and MHPAA were not found in
any plasma specimen from any subject. PAA was the
only metabolite in plasma that increased after
hydrolysis.
Metabolic products of tyrosine in plasma. The
PHPAA + PHBA peak was not detected in plasma
of any normal subject during fasting, but after the
load it was identified alter 60 mm in one man (Table
4). In contrast, this peak was observed in every
specimen from each uremic and hemodialysis pa-
tient. The fasting concentrations of PHPAA +
PHBA in the combined groups of uremic and dialysis
patients ranged from 6.1 to 66.2 j.moles/liter and
were inversely correlated with the GFR (r = —0.83,
P < 0.05, Fig. 5). Also, there was an inverse correla-
tion between the ratio of the PHPAA + PHBA peak
to the plasma tyrosine concentrations and the GFR
20
15
10
0 5 15 2410
Time, hr
Fig. 4. Mean cumulative expiration qf '4C02 in nornal subjects(open circles, N 5) and hemodial sis patients (x's, N = 5) after
an oral load of phenylalanine and a dose of L-['4C]-phenylalanine
(uniformly labeled). Statistically significant differences between
the groups are indicated by asterisks (P <0.05). Standard devia-
tions are denoted by vertical lines.
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Table 2. Urinary excretion of phenylalanine and tyrosine and their metabolitesa
Compound
Normal
subjects
Chronically uremic
patients
Hemodialysis
patients
Phenylalanine 124 80 325 (10—1088) 88 87
Metabolites of phenylalanine
phenylpynivic acid 0b 0b l4(0—57)
phenyllactic acid 42 21 6(0— l8) 37 22
o-hydroxyphenylacetic acid
free 45±21 79±53 33±21
conjugated
total
328 203
373 196
412 (4—1464)
491 (39—1493)
88 (9—250)
120 103d
phenylacetic acid
free 180± 148 59(0—139) 116(34—341)
conjugated 1304 398 1253 825 719 447
total 1483 439 1312 817 836 489
benzoic acid
free 83 72 19 (0—95) 25 (0—59)
conjugated
total
2167 724
2200 732
2220 917
2239 94
910 660
935 6781r
Total phenylalanine metabolites
free 350 181 158 84" 216 171
conjugated 3748 901 3886 1714 1761 I156"
grand total 4143 1050 4088 1744 1990 1222"
Tyrosine 113 86 126 (20—333) 45 43
Metabolites of tyrosine
p-hydroxyphenylacetic acid + p-hydroxybenzoic acid
tree 170 103 174 69 120 67
conjugated 181 110 319 149 219 200
total 350 55 492 8 339 256
a Values represent the mean SD; or if distribution is not normal, the values represent the mean and range. Values are
expressed as moles/24 hr.
' Not identified in any subject.
Found in one subject only.
d Differs from normal, P <0.05.
Differs from normal, P <0.01.
Differs from chronically uremic, P <0.05.
(r =
—0.92, P < 0.01). The PHPAA + PHBA peak
was significantly greater in the dialysis patients as
compared to the uremic subjects during fasting and
30 mm after the load. Alter the load, the PHPAA +
PHBA peak did not change in the uremic patients but
fell significantly at 180 and 240 mm in the dialysis
patients. In all specimens which were subjected to
mass spectrometry, PHBA accounted for about 90%
of the total concentration of PHBA and PHPAA.
There was no increase in concentration of PHPAA +
PHBA after hydrolysis.
PHPPA, PHPLA, and homogentisic acid were not
identified in plasma of any subject. There were more
unidentified peaks in the chromatograms of plasma
from the uremic and dialysis patients as compared to
the normal subjects.
Metabo/ites of phenylalanine in urine. BA ac-
counted for about 50% of the metabolites of phenyl-
alanine in the urine of each group during the 24 hr
after the load (Table 2). Urinary excretion of total BA
was significantly less in hemodialysis patients than it
was in normal subjects (P <0.05) or uremic patients
(P < 0.05). In every subject, over 90% of total
urinary BA was present in the bound form. FAA was
the second most abundant metabolite in urine; more
than 85% of total PAA was excreted in the bound
form in each group of subjects. Urinary OHPAA was
significantly less in dialysis patients than it was in
normal subjects (P < 0.05). The fraction of total
OHPAA which was conjugated tended to be higher
in uremic patients (0.05 < P < 0.1) and in dialysis
patients (P < 0.02) as compared to normal subjects.
Urinary excretion of PLA in the normal subjects was
similar to that in hemodialysis patients, but it was
greater than that in uremic patients (P <0.01). PPA
was detected in urine of only one hemodialysis pa-
tient and not in any normal subject or uremic patient.
MHPAA was not found in urine of any subject.
The urinary excretion of both conjugated and total
metabolites of phenylalanine in the normal subjects
was not different from that in the uremic patients,
but it was significantly greater in both groups than it
was in the hemodialysis patients. The calculated di-
etary intake of phenylalanine in the normal, uremic,
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Table 3. Plasma concentrations of phenylalanine metabolites before and after a phenylalanine loada
Phenylpyruvic Phenyllactic
Tim&'
mill Subjects
Phenylacetic acid, pnoles/liter
Free Conjugatede Totale
Benzoic
acid
acid acid Mandelic
acidprnoles/Iiter
0 Normal 74 32 12(2—31) 91 54 11(0—32) 0 0 0
Chronically uremic 59(13—173) 74(0—201) 105 73 2(0—9) 0 2(0—10) 0
Hemodialysis 58 37 58(4—143) 136 88 II 10 12 12 1 I 1 I
30 Normal 77 44 6(0—26) 0 0 0
Chronically uremic 56(12— 54) 2(0—10) 0 2(0—9) 0
Hemodialysis 57 40 10 5 16(0—34) 7(0—28) 2(0—6)
60 Normal 76 65 5(0—20) 0 0 0
Chronically uremic 57 50 2(0—10) 0 2(0—9) 0
Hemodialysis 73 62 5(0—15) 18 14 0 4(0—14)
90 Normal 119(32—154) 1(0—6) 2(0—10) 0 0
Chronically uremic 69 54 1(0—5) 0 2(0—10) 0
Hemodialysis 62 41 9(0—27) 23(0—140) 0 2(0—6)
120 Normal 94 78 30 24 116 69 2(0—10) 0 0 0
Chronically uremic 56 40 95(0—267) 141 116 2(0—6) 1 1 2(0—8) 0
Hemodialysis 37 25 110 49' 147 65 16(0—48) 16 14 0 0.3(0—1)
180 Normal 77 41 2(0—12) 0 0 0
Chronically uremic 53 33 3(0— 13) 1 1 2(0- 10) 0
Hemodialysis 36 26 27 25 52(0—144) 0 3(0—9)
240 Normal 68 38 22±17 81± 50 2(0—10) 0 0 0
Chronically uremic 57 38 l38(0—346) 180 l30 1(0—3) 0 2(0—12) 0
Hemodialysis 35 24 124 51" 162 27d 15(0—42) 30(0—78) 1 1 0
Concentration values represent the mean SD, or the mean and range when distribution was not normal.
0 time refers to blood collected immediately before ingestion of the load.
In a few subjects, conjugated phenylacetic acid was not measured; data from these subjects were excluded from calculation of the total
phenylacetic acid.d Differs from normal values obtained at the same time; P < 0.05.
Differs from normal values obtained at the same time, P < 0.01.
'Differs from values obtained at zero time (paired t test), P < 0.05.
and dialysis subjects during the 24 hr after the load
was 33 10, 15 3, and 28 4 mmoles, respec-
tively. The percentage of the total intake, including
the load, which was excreted as phenylalanine me-
tabolites during the 24 hr in the normal, uremic, and
dialysis subjects was 6.2 1.5, 7.6 2.4, 3.0 2.1,
respectively (dialysis vs. normal or uremic subjects,
P <0.05 and P = 0.05, respectively).
Tvrosine metabolites in urine. The only metabo-
lites of tyrosine identified in urine were PHPAA +
PHBA (Table 2). Free, conjugated, and total PHPAA
+ PHBA excretion were similar in the three groups.
Discussion
Phenylalanine, an essential amino acid, partici-
pates in a number of metabolic pathways. The major
one is irreversible hydroxylation to form tyrosine.
Three other pathways of phenylalanine metabolism,
normally of minor quantitative importance, are
transamination to phenylpyruvic acid (PPA), decar-
boxylation to form /3-phenylethylamine, and acetyla-
tion of the amino group. PPA may be reduced to
phenyllactic acid (PLA) or may undergo oxidative
decarboxylation to phenylacetic acid (PAA) which
may then be converted to benzoic acid (BA). PAA
Table 4. Plasma concentrations of tyrosine metabolites before and
after a phenylalanine load
p-Hydroxyphenylacetic
Times
mm Subjects
acid +
p-hydroxybenzoic acidb
j.unoleslliter
0 Normal
Chronically uremic
Hemodialysis
0
17 8
58 I l
30 Normal
Chronically uremic
Hemodialysis
0
18 13
52 21C
60 Normal
Chronically uremic
Hemodialysis
0
22 21
63 35
90 Normal
Chronically uremic
Hemodialysis
1 (0—5)
24 20
45 20
120 Normal
Chronically uremic
Hemodialysis
2 (0-10)
24 18
34 9"
180 Normal
Chronically uremic
Hemodialysis
1 (0—7)
23 17
36 8"
240 Normal
Chronically uremic
Hemodialysis
1 (0—6)
22 21
34 10"
0 time refers to blood collected immediately before ingestion
of the load.
b Values represent the mean SD or the mean and range if
distribution was not normal.
Differs from uremic patients at the same time, P < 0.05.
d Differs from fasting level, P < 0.05.
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may also be derived from /3-phenylethylamine by
oxidation. Tyrosine may be hydroxylated to form
dihydroxyphenylalanine (DOPA), iodinated to form
triiodothyronine (T3), or decarboxylated to form ty-
ramine. The major metabolic pathway for tyrosine,
however, is transamination to p-hydroxyphenylpy-
ruvic acid (PHPPA). Most PHPPA is converted to
homogentisic acid; the phenyl ring is then cleaved to
give fumaric and acetoacetic acid. PHPPA may also
be converted to p-hydroxyphenylacetic acid
(PHPAA) and then to p-hydroxybenzoic acid
(PHBA) [7]. There is some evidence that PHPAA
and PHBA may also be derived from phenylalariine
via hydroxylation of/3-phenylethylamine to tyramine
and oxidation of the latter compound [8]. Thus,
phenylalanine and tyrosine are both glycogenic and
ketogenic, and during normal metabolism they are
primarily converted to fat, carbohydrate, or carbon
dioxide. Many metabolic products, however, are not
completely oxidized, and in normal subjects they are
excreted in the urine.
Our findings demonstrate that in patients with
chronic uremia and in those on hemodialysis, as
compared to normal subjects, 1) plasma phenylala-
nine was greater after a phenylalanine load and fell
more slowly, 2) plasma tyrosine and the tyrosine/
phenylalanine ratio were lower before and after the
load, and 3) in the dialysis patients who ingested '4C-
phenylalanine, expiration of 14C02 was decreased.
These observations indicate that in renal failure,
there is a block in the conversion of phenylalanine to
tyrosine. This block, in association with reduced
renal clearance, theoretically could cause potentially
toxic metabolites of phenylalanine to accumulate in
plasma.
The tracer studies may provide more information
concerning the metabolic fate of phenylalanine after
the load. It is recognized that these studies were
carried out under nonsteady-state conditions, and
there was little information regarding pool size. Dif-
ferences in free phenylalanine pools, however, were
probably overwhelmed by the large magnitude of the
load, 42 mmoles/70 kg, compared to the estimated
total free phenylalanine pool of 2 to 3 mmoles [9].
Approximately 5% of the ingested carbon- 14 was
incorporated into plasma proteins, presumably as
phenylalanine and tyrosine. Grümer, Koblet, and
Woodard [10] estimated from phenylalanine turn-
over studies that plasma protein turnover represents
less than 10% of total daily protein turnover. Thus,
almost certainly, a large percentage of the ingested
carbon-14 was incorporated into body protein as a
result of normal protein turnover. There was proba-
bly little if any net synthesis of protein during the
study, and the labeled phenylalanine and tyrosine
that entered protein were replaced by unlabeled phe-
nylalanine and tyrosine released from protein. Some
of the label may have been incorporated into carbo-
hydrate or fat.
In the normal and dialysis subjects 24 hr after the
load, 0.2% and 2.2% of ingested carbon-14, respec-
tively, was in the nonprotein portion of plasma, and,
hence, and 1% and 11% of the ingested dose was in
the nonprotein fraction of extracellular fluid. Uri-
nary excretion of carbon-14 during this 24 hr was
small in both groups but greater in the normal sub-
jects (2.6% vs. 0.2% of the ingested dose). The non-
protein-bound label in extracellular fluid and urine
was present in phenylalanine, tyrosine, and their
metabolites.
About 28% of the ingested label appeared as 'CO2
during the first 24 hr in the normal subjects, as
x
x
80
60
40
r = —0.83
V = —3.40x + 63.41
P<0.05
10
GFR, mi/mm
Fig. 5. The relationship of postahsorptii'e plasma p-by rox-
phenvlacetic acid (PHPAA) + p-hvdroxvbenzoic acid (PI-IBA) to
the GFR in chronically uren?ic patients (indicated by closed cir-
cles) and /iemodialvsis patients (indicated by x's).
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compared to 20% in the dialysis patients. Since much
of the labeled phenylalanine and tyrosine were ex-
changed in protein for the nonlabeled amino acids,
these values of 28% and 20% must represent lower
limits to the fraction of phenylalanine which was
oxidized.
The foregoing considerations suggest that the deg-
radation of phenylalanine via tyrosine to carbon
dioxide was somewhat greater in the normal subjects
as compared to the dialysis patients. In the dialysis
patients as well as the normal subjects, however, the
hydroxylation of phenylalanine to tyrosine and its
subsequent degradation to carbon dioxide was still
the primary route for utilization of the load. These
observations are in direct contrast to the response of
phenylketonuric patients to a phenylalanine load
where most of the ingested load is excreted in the
urine either unchanged or as non-para-hydroxylated
metabolites [6].
The finding that after the load '4C02 expiration
was lower in the dialysis patients who were studied
an average of 61 hr as compared to those studied 15
hr after the end of a dialysis therapy suggest that a
dialyzable uremic toxin may adversely affect phenyl-
alanine or tyrosine metabolism. These conclusions
are tentative because of the small number of patients
studied.
The present study also provides the first evidence
for a relationship between protein intake and the rate
of phenylalanine degradation in normal man. In the
normal subjects ingesting 40-g protein diets as com-
pared to those eating their regular unrestricted diets,
there was a greater rise in plasma phenylalanine and
a lower rate of expiration of 14C02 after the load.
These results suggest that the combined rates of
hydroxylation of phenylalanine and oxidation of its
metabolites were decreased in subjects receiving the
lower protein diet. These findings are not unex-
pected. Wang et al [11] and Young and Parsons [121
have shown that in liver of both chronically uremic
and control rats, activity of phenylalanine hydroxyl-
ase is directly related to protein intake. Also, kinetic
studies in chronically uremic humans suggest that
tyrosine degradation is directly related to protein
intake [3].
Even when the normal subjects ingesting the 40-g
protein diets were compared to the uremic and dialy-
sis patients who were eating similar or greater quan-
tities, the differences in phenylalanine and tyrosine
levels and '4C02 expiration persisted but were not as
marked. The results of this study therefore suggest
two acquired conditions which affect phenylalanine
metabolism in man: 1) renal failure and 2) dietary
protein intake. Since uremic patients usually ingest
low protein diets, it is possible that both of these
factors contribute to abnormal phenylalanine metab-
olism in renal failure.
A surprising finding was the relatively low plasma
levels of phenylalanine metabolites in the patients
with renal failure. PLA and possibly MA were in-
creased slightly in the uremic or dialysis patients
before and/or after the phenylalanine load. PPA rose
markedly after the load in one hemodialysis patient
but in other patients was increased slightly or not at
all. The metabolities PAA, BA, OHPAA, and
MHPAA were not increased in any uremic or dialy-
sis patient. The tyrosine metabolites, PHPPA,
PHPLA, and homogentisic acid, were not detected
in plasma or urine from any subject.
A striking observation, however, was the large
chromatographic peak for the phenolic acids,
PHPAA + PHBA, in plasma of uremic and dialysis
patients but not in that of normal subjects. The val-
ues, which ranged from 6 to 66 /Lmoles/liter, were
sometimes as high as the fasting levels of phenylala-
nine and tyrosine, and these were the only free me-
tabolites of either amino acid which were markedly
elevated in these patients. The preliminary results
from mass spectrometry indicate that PHBA ac-
counted for about 90% of the total concentration of
the two metabolic products of tyrosine. It is of inter-
est that plasma values for PHPAA + PHBA were
similar to the levels of free phenolic acids (7 to 102
mo1es/liter) reported by other investigators in
uremic patients [13, 14]. Hence, PHBA and/or
PHPAA are probably the major free phenolic com-
pounds which accumulate in renal failure. It is not
clear why the ratio of plasma PHPAA + PHBA to
tyrosine was inversely correlated with the GFR. Pro-
gressive impairment in urinary clearance of PHPAA
+ PHBA with falling GFR may be a cause. Increased
conversion of tyrosine to PHPAA and PHBA could
also explain this finding.
It was also surprising that no free metabolite of
phenylalanine or tyrosine increased significantly in
any of the three groups after the phenylalanine load,
although values in individual patients sometimes
rose substantially. By comparison, plasma phenylal-
anine increased 10 to 15 times, and tyrosine doubled
or tripled. Conjugated PAA, which tended to be
elevated in the fasting state in both groups of pa-
tients, increased significantly in the uremic patients
and became greater than normal in the dialysis pa-
tients after the load. The increased conjugated PAA
in the uremic and dialysis patients after the load may
reflect enhanced production or delayed renal excre-
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tion (Table 2). The conjugated PAA was probably
primarily phenylacetylgiutamine, which is the most
abundant conjugate of PAA in normal people [15].
Fnmpter, Thompson, and Luckey reported elevated
plasma phenylacetyiglutamine levels in acutely and
chronically uremic patients who were not fasting
16].
It is of interest that the urinary excretion of every
measured free and conjugated metabolite of phenyl-
alanine and tyrosine was normal in the uremic and
dialysis patients despite their markedly reduced
GFR's. A comparison of the plasma and urinary
levels of these compounds to the GFR indicates that
there may be increased fractional excretion of these
metabolites. This may be due to decreased renal
tubular reabsorption. Since the clearance for some
compounds, however, may have exceeded the GFR,
tubular secretion may also be present. This could
account for the relatively high clearance of PLA and
conjugated PAA in the dialysis patients and possibly
of conjugated PAA in the uremic subjects. Evidence
for renal tubular secretion of phenylpyruvic acid [17]
and phenylacetylglutamine [18] has been reported.
In the three groups of subjects, urinary PPA was
identified only in the dialysis patient who manifested
the highest plasma PPA both before and after ingest-
ing the phenylalanine. Giordano et al reported in-
creased urinary PPA after a phenylalanine load in
uremic patients but not in normal subjects [191. Pick-
ford, McGale, and Aber, however, also found no
increase in PPA excretion after a phenylalanine load
in either uremic or normal subjects [1]. The plasma
and urinary data in the present study are consistent
with relatively minor increased production, and/or
decreased degradation of PPA in renal failure.
The results of this study indicate that in renal
failure the conversion of phenylalanine to tyrosine is
impaired, and the degree of the block is related to the
severity of renal failure. The magnitude of impair-
ment, however, appears small. Even when the
uremic or dialysis patient is stressed with a phenylal-
anine load, the great fraction of phenylalanine is
metabolized through normal pathways, albeit some-
what more slowly than normal. The metabolites of
phenylalanine in plasma were only slightly in-
creased, if at all, and this appeared to be primarily
due to decreased renal clearance rather than in-
creased synthesis through metabolic shunts. An ex-
ception to this was the elevated PPA levels in some
patients. In fact, the highest plasma levels of metabo-
lites found in the patients were for PHPAA +
PHBA, which were probably derived from tyrosine.
The present observations also indicate that in normal
subjects the magnitude of protein intake will affect
the rate of degradation of phenylalanine.
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